Related Experiment Videos
Future directions with platelet growth factors.
1Hematology/Oncology Unit, Massachusetts General Hospital, Harvard Medical School, Boston 02114, USA.
Seminars in Hematology
|June 1, 2000
Summary
Recombinant thrombopoietin (TPO) and related molecules effectively reduce chemotherapy-induced low platelets. Future research will establish their role in various conditions and stem cell expansion.
Area of Science:
- Hematology
- Oncology
- Regenerative Medicine
Background:
- Thrombopoietin (TPO) and its ligands, including recombinant human TPO (rhTPO) and pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF), have been investigated for over six years.
- These agents have demonstrated efficacy in mitigating thrombocytopenia (low platelet counts) in patients undergoing nonmyeloablative chemotherapy.
Purpose of the Study:
- To explore further clinical applications of c-Mpl ligands, focusing on novel administration routes and treatment of non-chemotherapy-induced thrombocytopenia.
- To evaluate the potential of TPO and its analogs in improving platelet yields for apheresis donors and in the ex vivo expansion of stem cells.
- To investigate the radioprotective capabilities of TPO in preventing radiation-induced apoptosis of pluripotent stem cells.
Main Methods:
- Clinical investigation of rhTPO and PEG-rHuMGDF, including intravenous administration.
- Exploration of fusion proteins (interleukin-3-TPO) and peptide mimetics.
- Application in treating myelodysplastic syndrome (MDS), idiopathic thrombocytopenic purpura (ITP), HIV-related ITP, and liver disease.
- Assessment of effects on apheresis donor platelet yields and ex vivo stem cell expansion.
- Evaluation as a radioprotectant for pluripotent stem cells.
Main Results:
- rhTPO and PEG-rHuMGDF effectively reduce thrombocytopenia associated with nonmyeloablative chemotherapy.
- PEG-rHuMGDF has shown considerable success in increasing platelet yields in apheresis donors.
- Extensive research has been conducted on using TPO for ex vivo expansion of pluripotent stem cells.
Conclusions:
- Further clinical development of c-Mpl ligands is warranted, exploring intravenous administration, fusion proteins, and peptide mimetics.
- TPO and its analogs hold promise for treating various non-chemotherapy-induced thrombocytopenic conditions.
- The role of TPO in enhancing apheresis yields and in ex vivo stem cell expansion is a significant area of ongoing investigation.
- TPO may function as a radioprotectant, preserving pluripotent stem cells from radiation damage.
- The clinical utility of rhTPO, PEG-rHuMGDF, and related molecules is expected to be established for both chemotherapeutic and non-chemotherapeutic indications.